ABSTRACT This supplement request is for a Phase 3, randomized, observer-blind, placebo-controlled study to evaluate the efficacy, safety and immunogenicity, of a SARS-CoV-2 recombinant spoke protein nanoparticle vaccine (SARS-CoV-2 rS) with Matric-M1TM adjuvant in adult participants over 18 years of age who have no known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 and/or SARS-CoV-2 infection. This request also relates to other COVID 19 activities.